Dopaminergic neuronal integrity in parkinsonism associated with liver cirrhosis

NeuroToxicology

Volumn 31, Issue 4, 2010, Pages 351-355

  Kim, Jong Min ^a   Kim, Ji Seon ^a   Jeong, Sook Hyang ^a   Kim, Yu Kyeong ^a   Kim, Sang Eun ^a   Kim, Suk Hwan ^b   Kim, Yangho ^b  

^a Seoul National University Bundang Hospital   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

Chronic acquired hepatocerebral degeneration; Dopamine transporter; Liver cirrhosis; Manganese; Parkinson's disease; Parkinsonism

Indexed keywords

CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; DOPAMINE TRANSPORTER; FLUOROPROPYL 2 CARBOMETHOXY 3 (4 IODOPHENYL)TROPANE I 123; IODINE 123; LEVODOPA; RADIOISOTOPE; UNCLASSIFIED DRUG; 2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; RADIOPHARMACEUTICAL AGENT; TROPANE DERIVATIVE;

ADULT; AGED; ARTICLE; BASAL GANGLION; BRADYKINESIA; CLINICAL ARTICLE; COMORBIDITY; DOPAMINERGIC NERVE CELL; DRUG DOSE ESCALATION; DYSARTHRIA; FEMALE; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS; MALE; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PARKINSONISM; PORTAL HYPERTENSION; PRIORITY JOURNAL; RIGIDITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; CASE REPORT; COMPLICATION; DIAGNOSTIC USE; DRUG RESISTANCE; METABOLISM; MIDDLE AGED; NERVE CELL; PARKINSONIAN DISORDERS; PROCEDURES; SCINTISCANNING;

AGED; BASAL GANGLIA; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DRUG RESISTANCE; FEMALE; HUMANS; LEVODOPA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NEURONS; PARKINSONIAN DISORDERS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 77953539479     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuro.2010.05.002     Document Type: Article

References (35)

1. Adams R.D., Victor M. Acquired (non-Wilsonian) hepatocerebral degeneration. Principles of neurology 1985, 800-802. McGraw-Hill, New York, NY. 3rd ed. B.K. Barry, M. Schwartz, E.J. Scott (Eds.).
2. Ashizawa R. Uber einen sektionsfall von chronischer manganvergiftung. Jpn J Med Sci Trans Sect VIII: Int Med Pediat Psychiat 1927, 1:173-191.
3. Bang S.-J., Choi S.H., Park N.H., Shin J.W., Choy N., Kim S.H., et al. High pallidal T1 signal is rarely observed in obstructive jaundice, but is frequently observed in liver cirrhosis. J Occup Health 2007, 49:268-272.
4. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington, Clinical, morphological and neurochemical correlations. J Neurol Sci 1973, 20:415-455.
5. Brunberg J.A., Kanal E., Hirsch W., Van Thiel D.H. Chronic acquired hepatic failure: MR imaging of the brain at 1.5T. AJNR Am J Neuroradiol 1991, 12:909-914.
6. Burkhard P.R., Delavelle J., Du Pasquier R., Spahr L. Chronic parkinsonism associated with cirrhosis: a distinct subset of acquired hepatocerebral degeneration. Arch Neurol 2003, 60:521-528.
7. Calne D.B., Chu N.S., Huang C.C., Lu C.S., Olanow W. Manganism and idiopathic parkinsonism: similarities and differences. Neurology 1994, 44:1583-1586.
8. Chen M.K., Lee J.S., McGlothan J.L., Furukawa E., Adams R.J., Alexander M., et al. Acute manganese administration alters dopamine transporter levels in the non-human primate striatum. Neurotoxicology 2006, 27:229-236.
9. Choi Y., Park J.K., Park N.H., Shin J.W., Yoo C.-I., Lee C.R., et al. Whole blood and red blood cell manganese reflected signal intensities of T1-weighted MRI better than plasma manganese in liver cirrhotics. J Occup Health 2005, 47:68-73.
10. Cotzias G.C. Metabolic modification of some neurologic disorders. JAMA 1969, 210:1255-1262.
11. Guilarte T.R., Burton N.C., McGlothan J.L., Vernia T., Zhou Y., Alexander M., et al. Impairment of nigrostriatal dopamine neurotransmission by manganese is mediated by pre-synaptic mechanism(s): implications to manganese-induced parkinsonism. J Neurochem 2008, 107:1236-1247.
12. Hitoshi S., Terao Y., Mizuno T., Takeda K., Sakuta M. A case of portal-systemic encephalopathy presenting characteristic MR images in globus pallidus, hypothalamus, corpus callosum, pontine base, and middle cerebellar peduncle. Clin Neurol 1992, 32:217-219.
13. Huang C.C., Chu N.S. Manganese-induced parkinsonism, Parkinson's disease, and welding. Neurotoxicity syndromes 2007, 221-247. Nova Science Publishers, Inc., New York, NY. L.R. Webster (Ed.).
14. Inoue E., Hori S., Narumi Y., Fujita M., Kuriyama K., Kadota T., et al. Portal systemic encephalopathy: presence of basal ganglia lesions with high signal intensity on MR images. Radiology 1991, 179:551-555.
15. Jog M., Lang A. Chronic acquired hepatocerebral degeneration: case reports and new insights. Mov Disord 1995, 10:714-722.
16. Kim Y. High signal intensities on T1-weighted MRI as a biomarker of exposure to manganese. Ind Health 2004, 42:111-115.
17. Kim Y. Neuroimaging in manganism. Neurotoxicology 2006, 27:369-372.
18. Kim Y., Kim K.S., Yang J.S., Park I.J., Kim E., Jin Y., et al. Increase in signal intensities on T1-weighted magnetic resonance images in asymptomatic manganese-exposed workers. Neurotoxicology 1999, 20:901-907.
19. Kim Y., Kim J., Ito K., Lim H.-S., Cheong H.-K., Kim J.Y., et al. Idiopathic parkinsonism with superimposed manganese exposure: utility of positron emission tomography. Neurotoxicology 1999, 20:249-252.
20. Kim Y., Kim J.M., Kim J.W., Yoo C., Lee C.R., Lee J.H., et al. Dopamine transporter density is decreased in parkinsonian patients with a history of manganese exposure: what does it mean?. Mov Disord 2002, 17:568-575.
21. Kim J., Kim J.M., Kim Y.K., Shin J.W., Choi S.H., Kim S.E., et al. Dopamine transporter SPECT of a liver cirrhotic with atypical parkinsonism. Ind Health 2007, 45:497-500.
22. Kim J.M., Hong S., Kim G.P., Choi Y.J., Kim Y.K., Park S.S., et al. Importance of low range CAG expansion and CAA interruption in SCA2 Parkinsonism. Arch Neurol 2007, 64:1510-1518.
23. Klos K.J., Ahlskog J.E., Josephs K.A., Fealey R.D., Cowl C.T., Kumar N. Neurologic spectrum of chronic liver failure and basal ganglia T1 hyperintensity on magnetic resonance imaging: probable manganese neurotoxicity. Arch Neurol 2005, 62:1385-1390.
24. Kulisevsky J., Ruscalleda J., Grau J.M. MR imaging of hepatocerebral degeneration. AJNR Am J Neuroradiol 1991, 12:527-528.
25. Lee J., Lacomis D., Comu S., Jacobsohn J., Kanal E. Acquired hepatocerebral degeneration: MR and pathologic findings. AJNR Am J Neuroradiol 1998, 19:485-487.
26. Lockwood A.H., Yap E.W., Rhoades H.M., Wong W.H. Altered cerebral blood flow and glucose metabolism in patients with liver disease and minimal encephalopathy. J Cereb Blood Flow Metab 1991, 11:331-336.
27. Lucchini R.G., Kim Y. Health effects of manganese. Metals and neurotoxicity 2009, 119-147. Society for Science and Environment, India. M. Vojtisek, R. Prakash (Eds.).
28. Mena I., Court J., Fuenzalida S., Papavasiliou P.S., Cotzias G.C. Modification of chronic manganese poisoning. Treatment with L-dopa or 5-OH tryptophane. N Engl J Med 1970, 282:5-10.
29. Mousseau D.D., Perney P., Layrargues G.P., Butterworth R.F. Selective loss of pallidal dopamine D2 receptor density in hepatic encephalopathy. Neurosci Lett 1993, 162:192-196.
30. Park N.H., Park J.K., Choi Y., Yoo C.-I., Lee C.R., Lee H., et al. Whole blood manganese correlates with high signal intensities on T1-weighted MRI in patients with liver cirrhosis. Neurotoxicology 2003, 24:909-915.
31. Park J., Kim Y., Kim J.W. High signal intensities on T1-weighted MRI in the spectrum of manganese symptomatology. Neurotoxicity syndromes 2007, 249-260. Nova Science Publishers, Inc., New York, NY. L.R. Webster (Ed.).
32. 18F]FDOPA PET and clinical features in parkinsonism due to manganism. Mov Disord 2005, 20:492-496.
33. Scholten J.M. On manganese encephalopathy. Folia Psychiatr Neurol 1953, 56:878-884.
34. Tarter R.E., Hays A.L., Sandford S.S., Van Thiel D.H. Cerebral morphological abnormalities associated with non-alcoholic cirrhosis. Lancet 1986, 2:893-895.
35. Victor M., Adams R.D., Cole M. The acquired (non-wilsonian) type of chronic hepatocerebral degeneration. Medicine 1965, 44:345-396.